Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Annual Report · 10-K

Assertio Holdings, Inc.

Annual Report

Filed Mar 11, 2024Accepted Mar 11, 2024, 5:09 PM EDTCIK 1808665Accession 0001808665-24-000012
Share

Company context

Assertio is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. Our focus is on supporting patients by marketing products primarily in the oncology market. To learn more about Assertio, visit www.assertiotx.com.

Historical securities (1)

Recent company filings

  1. 15-12G filingJul 31, 2026
  2. 25-NSE - filed by Nasdaq Stock Market LLC regarding Assertio Holdings, Inc.Jul 7, 2026
  3. 15-12G filingJun 26, 2026
  4. EFFECT filingJun 17, 2026
  5. EFFECT filingJun 17, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗